Baudax Bio
-
Malvern-Based Baudax Bio Once Again Seeking to Extend Its Reorganization Plan Deadline
Malvern-based Baudax Bio is seeking a fifth extension on its reorganization plan deadline after filing for bankruptcy a year ago, writes John George for the…
-
Malvern-Based Biotech Company Inherits Cell Therapy Treatments After New Aquisition
A Malvern-based biotech company is making an advantageous acquisition. Baudax Bio will be inheriting an abundance of products following its transaction with Maryland-based TeraImmune. Baudax’s…
-
After Net Loss of Nearly $50 Million, Malvern-Based Pharma Company Completes Public Stock Offering
Malvern-based pharmaceutical company Baudax Bio has completed $5 million in stock sales, writes John George for the Philadelphia Business Journal. The proceeds made from the…
-
Malvern-Based Pharmaceutical Company Expects to Raise $6.2 Million from Public Stock Offering
Malvern-based Baudax Bio is selling a little over 11.8 million shares of its common stock in a public stock offering that is expected to raise…
-
Malvern’s Baudax Bio Closes $50 Million Loan Deal to Officially Launch Its Non-Opioid Pain Med
Malvern-based Baudax Bio has signed a loan deal with Marathon Asset Management worth $50 million to support the launch of its intravenous and non-opioid pain…
-
Malvern’s Baudax Bio Turns to Nontraditional Methods to Promote New, Non-Opioid Pain Med
Baudax Bio launched its new, non-opioid pain medication earlier this week, but due to the ongoing coronavirus crisis, the Malvern-based company is relying on non-traditional…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
